Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 3/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846913 | 1.00 | MDM2 (0.53) | MDM2MAPTNPSR1TDP1KDM4E | |
| SCHEMBL13401516 | 0.92 | MDM2 (0.52) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL16325412 | 0.92 | MDM2 (0.52) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL17002047 | 0.89 | MDM2 (0.51) | MDM2MAPTNPSR1TDP1CA1 | |
| SCHEMBL18758919 | 0.87 | CA1 (0.55) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL23445925 | 0.87 | TLR2 (0.52) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL19602150 | 0.87 | TLR2 (0.52) | MDM2CA1CA2TLR2TLR1 | |
| SCHEMBL30783495 | 0.86 | TLR2 (0.54) | MDM2MAPTNPSR1TDP1KDM4E | |
| SCHEMBL27261267 | 0.86 | TLR2 (0.54) | MDM2MAPTNPSR1TDP1KDM4E | |
| SCHEMBL16325411 | 0.86 | MDM2 (0.47) | MDM2CA1CA2TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MDM2 2451/4885MAPT 3090/4885NPSR1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.